Literature DB >> 9875657

Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C.

G Tappero, M Ballaré, M Farina, F Negro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9875657     DOI： 10.1016/s0168-8278(98)80138-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  3 in total

1.  Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Tsugiko Oze; Naoki Hiramatsu; Nao Kurashige; Natsuko Tsuda; Takayuki Yakushijin; Tatsuya Kanto; Tetsuo Takehara; Akinori Kasahara; Michio Kato; Harumasa Yoshihara; Kazuhiro Katayama; Shinji Kubota; Taizo Hijioka; Kazunobu Ishibashi; Masahide Oshita; Hideki Hagiwara; Yoshimichi Haruna; Eiji Mita; Shinji Tamura; Norio Hayashi
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

2.  Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.

Authors:  J M Cullen; D H Li; C Brown; E J Eisenberg; K C Cundy; J Wolfe; J Toole; C Gibbs
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

3.  Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial.

Authors:  Jiska M Balk; Guido Rmm Haenen; Özgür M Koc; Ron Peters; Aalt Bast; Wim Jf van der Vijgh; Ger H Koek
Journal:  Pharmgenomics Pers Med       Date:  2015-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.